Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics.
J Microencapsul
; 38(3): 192-202, 2021 May.
Article
em En
| MEDLINE
| ID: mdl-33530812
ABSTRACT
AIM:
Nano drug delivery systems can provide the opportunity to reduce side effects and improve the therapeutic aspect of a variety of drugs. Bortezomib (BTZ) is a proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma. Severe side effects of BTZ are the major dose-limiting factor. Particulate drug delivery systems for BTZ are polymeric and lipidic drug delivery systems. This review focussed on lipidic-nano drug delivery systems (LNDDSs) for the delivery of BTZ.RESULTS:
LNDDSs including liposomes, solid lipid nanoparticles, and self-nanoemulsifying drug delivery systems showed reduce systemic side effects, improved therapeutic efficacy, and increased intestinal absorption. Besides LNDDSs were used to target-delivery of BTZ to cancer.CONCLUSION:
Overall, LNDDSs can be considered as a novel delivery system for BTZ to resolve the treatment-associated restrictions.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Sistemas de Liberação de Medicamentos
/
Nanopartículas
/
Inibidores de Proteassoma
/
Bortezomib
/
Lipídeos
Limite:
Animals
/
Humans
Idioma:
En
Revista:
J Microencapsul
Assunto da revista:
FARMACIA
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Irã